The survivorship needs of patients living with chronic cancer (CC) and their use of survivorship care plans (SCPs) have been overlooked and underappreciated. METHODS: A convenience sample of 39,088 SCPs completed for cancer survivors with an Internet-based SCP tool was examined; it included 5847 CC survivors (15%; CC was defined as chronic leukemia and/or recurrent/ metastatic cancer of another nature). Patient-reported treatment effects and follow-up care patterns were compared between CC survivors and survivors treated with curative intent (CI). Responses from a follow-up survey regarding SCP satisfaction and use were reviewed. RESULTS: CC survivors had greater odds of experiencing multiple treatment-related effects than survivors treated with CI; these effects included fatigue, cognitive changes, dyspnea, peripheral neuropathy, lymphedema, and erectile dysfunction. Nearly half of CC survivors were managed by an oncologist alone, and they were less likely than CI patients to be comanaged by a primary care provider and an oncologist. Fewer SCPs were generated by health care providers (HCPs) for CC survivors versus CI survivors. A smaller proportion of CC users versus CI users rated their experience and satisfaction with the SCP tool as very good or excellent, and CC users were less likely to share the HCP summary with their health care team. CONCLUSIONS: A substantial number of CC survivors, often considered incurable but treatable, seek survivorship support. Tools to facilitate participation, communication, and coordination of care are valuable for these patients, and future iterations of SCPs should be designed to address the particular circumstances of living with CC. Cancer 2017;123:4268-76.
INTRODUCTION
A cancer survivor is defined as any individual "from the time of diagnosis, through the balance of his or her life," and this definition includes those living with chronic cancer, whether in the form of metastatic or recurrent solid tumors, leukemia, or lymphoma.
1,2 Nearly 14.5 million cancer survivors are living in the United States today, with this number projected to increase to 19 million by 2024. 3 Although there are no precise estimates of how many of these survivors are living with chronic cancer (CC), we can expect this population to grow as advances in treatments and supportive care expand our capacity to control and manage CC patients for long periods of time, even when a cure may not be possible. [3] [4] [5] [6] Survivorship care plans (SCPs) were introduced by the Institute of Medicine in 2005 as documents that summarize a survivor's cancer history and establish a follow-up plan beyond active treatment with the intent of facilitating communication and assigning responsibilities across treatment teams, caregivers, and survivors themselves. 7, 8 The use of SCPs for patients living with CC has not yet been embraced by the medical community, as illustrated by their exclusion from the American College of Surgeons Commission on Cancer standards for SCPs, and it remains a neglected topic of research. 9 Literature investigating the needs of patients living with CC is scarce too, and where it exists, it portrays a population of cancer survivors with multiple challenges in care. [10] [11] [12] Many of these issues, such as a lack of integration between treatment services and difficulty in coping with the physical and psychosocial effects of treatment, are exactly those that SCPs seek to address and ameliorate. 13 The specific needs of those living with CC and how they engage in their health must be better understood for effective survivorship care to be delivered. 14 To that end, we examined data obtained from a convenience sample of SCPs generated for cancer survivors via a publically available Internet-based SCP tool. We present patterns in treatment-related effects, follow-up care, and SCP use in CC survivors, and we compare these data with those from patients treated with curative intent (CI).
MATERIALS AND METHODS

SCP
The OncoLife SCP program was designed by a team of oncology nurses and physicians at the Abramson Cancer Center of the University of Pennsylvania and was launched on OncoLink (https://www.oncolink.org/) in 2007. OncoLink was the first and is one of the largest cancer information sites on the Internet aiming to support patients, caregivers, and providers through the provision of cancer-related tools and educational materials. At present, the care plan tool is publically accessible via https:// www.oncolink.org/ and https://oncolife.oncolink.org/. Users are able to find this resource independently or on the basis of a recommendation from their health care provider (HCP). For a portion of the time during which data were gathered for this study, the tool was also available as the Livestrong Care Plan at http://www.livestrongcareplan.org.
This resource enables patients, caregivers, and HCPs to input data regarding the demographics, diagnosis, treatment course, and patient-related outcomes to provide personalized, comprehensive health care recommendations for future care. 15 These recommendations are evidence-or consensus-based wherever possible and are in accordance with guidelines provided by the National Cancer Institute and the American Society of Clinical Oncology. In areas for which formalized guidelines are not available, the care plan's recommendations are based on our institution's own practice and guidance from leaders in the field of survivorship medicine.
Two versions of the tool exist: one intended for HCPs to complete for their patients and another intended for survivors or their proxies to complete. The patient plan includes additional questions about late and longterm effects. Upon the completion of the tool's queries, a personalized care plan and HCP summary is generated on the basis of the user's responses and is delivered in PDF format via e-mail. A 5-question, 1-page user satisfaction survey is provided through an optional link accessible upon receipt of the care plan.
Data Collection
All users were first queried about demographic and treatment information. If they were using the patient plan, the users were then queried about long-term and late effects; the questions were customized to each survivor's specific treatments and/or primary cancer diagnosis. Because of the adaptive nature of the questioning, not all users were asked every question. Answer choices were typically formatted as yes, no, or I don't know unless otherwise specified.
CC survivors were defined as those who reported living with metastatic disease, recurrent disease, or a second diagnosis of cancer as well as those diagnosed with chronic lymphocytic leukemia or chronic myelogenous leukemia. The remaining survivors were those treated with CI for early-stage or locally advanced cancers, and they are herein referred to as CI survivors.
Institutional review board approval was obtained before any study proceedings. For this study, data were obtained from the survivor user database for all users since the launch of the eighth version from October 2011 to December 2016.
Statistical Analysis
Demographic, cancer care, and treatment-related effect data were reviewed as well as follow-up survey responses. We used 2-sample t tests for continuous variables and chisquare tests for categorical variables to assess the statistical significance of comparisons of these 2 survivor populations.
Univariate logistic regression analysis was used to test the association between cancer chronicity and treatment-related effects. Treatment-related effects were treated as a binary variable: yes versus no and I don't know. Those variables that attained or trended toward statistical significance (P .10) in the univariate analysis were included in multivariate modeling. All statistical tests were 2-sided, and P < .05 was considered statistically significant.
RESULTS
Population Characteristics and Demographic Details
Of the 39,088 users who developed a care plan during the study period, 15% (n 5 5847) were patients with CC: 8% (n 5 3223) reported "a recurrence of a previous cancer or new diagnosis of a second cancer," 6% (n 5 2420) reported "living with metastatic cancer," and 0.7% (n 5 256) had a diagnosis of chronic lymphocytic leukemia or chronic myelogenous leukemia.
The mean age at the time of SCP completion was 57.6 and 56.5 years for CC and CI survivors, respectively. A total of 59% and 42% of CC and CI survivors, respectively, were at least 2 years from their diagnosis; 41% and 28% were at least 5 years from their diagnosis. Further population characteristics for both CC and CI survivors are summarized in Table 1 .
Breast cancer represented the greatest number of both CC and CI survivors (31% and 53%, respectively; Table 2 ). The 5 most common cancers for both of these cohorts additionally included lung cancer, prostate cancer, colon cancer, and lymphoma. Survivors with metastatic or recurrent cancer represented a substantial proportion of those diagnosed with lung cancer (27%), melanoma (30%), brain cancer (37%), bladder cancer (32%), and pancreatic cancer (30%).
Patient-Reported Outcomes
Treatment-related effects were explored from SCPs generated by the patient version of this tool (n 5 19,560). Upon univariate modeling, CC was associated with increased odds of experiencing a variety of treatmentrelated effects (Table 3 ). Significant differences were observed after adjustments for patient and cancer care characteristics for most sequelae, including fatigue (odds ratio [OR], 1.7; P < .01), cognitive changes (OR, 1.5; P < .01), dyspnea (OR, 2.1; P 5 .02), diagnosis of kidney problems (OR, 1.9; P 5 .01), diagnosis of liver disease (OR, 4.5; P 5 .01), abnormal liver function tests (OR, 2.3; P 5 .01), peripheral neuropathy (OR, 1.2; P 5 .04), lymphedema (OR, 1.5; P < .01), and erectile dysfunction (OR, 1.5; P 5 .04).
Follow-Up Care and Survivorship Health
Details regarding patients' survivorship care were explored (Table 4) . A greater proportion of SCPs were self-made by CC survivors (36%) versus CI survivors (25%) as well as family or friends (10% vs 3%, respectively; P < .01). Reciprocally, 50% and 66% of plans were completed by HCPs for their CC and CI survivors, respectively (P < .01; Table 4 ). Nurses and nurse practitioners represented the majority (86%) of HCPs who accessed the tool for their patients.
A greater proportion of CC patients were managed by an oncologist alone (48%) in comparison with CI survivors (36%), whereas they were less likely to be comanaged by a primary care provider (PCP) and an oncologist (41% vs 50%, respectively; P < .01).
Use and Satisfaction of an Online SCP Tool
Optional satisfaction surveys were completed by 7% of the CC survivors (n 5 392) and 5% of the CI survivors (n 5 1689) after the receipt of their SCP, with the results detailed in Table 5 . A smaller proportion of CC survivors versus CI survivors rated their experience and satisfaction with the SCP tool as very good (54% vs 62%; P 5 .01) or excellent (45% vs 55%; P 5 .01). More of the CC survivors (40%) versus the CI survivors (32%; P < .01) thought that the plan could use more information or did not contain enough information. CC survivors were less likely to report that they planned on sharing the provided HCP summary with their health care team (66% vs 74%, respectively; P < .01).
Subset Analysis of Breast Cancer Survivors
We additionally analyzed the subset of survivors with a diagnosis of breast cancer to explore whether our observations regarding CC were consistent under the condition of having a relatively favorable prognosis because these patients may be more likely to engage with survivorship interventions on account of their prolonged survival. The mean age at the time of SCP receipt for chronic breast cancer survivors was 58 years (vs 58 years for survivors with chronic nonbreast cancer; P 5 .99) with a mean time of 5 years from diagnosis (vs 4 years; P < .01); 79% were white (vs 81%; P 5 .03).
Similar discrepancies were observed between CC and CI breast cancer survivors, and they included a greater rate of self-completion of SCPs (31% vs 22%; P < .01) and a lower rate of comanagement by PCPs and oncologists (44% vs 53%; P < .01). Chronic breast cancer survivors were demonstrated to have increased odds of treatment-related effects after we had controlled for Original Article patient and cancer care characteristics, including fatigue (OR, 1.5; P < .01), perceived cognitive changes (OR, 1.4; P 5 .02), a new diagnosis of kidney (OR, 5.1; P 5 .03) or liver disease (OR, 5.1; P 5 .01), the development of abnormal liver function tests (OR, 3.5; P < .01), and lymphedema (OR, 1.5; P 5 .01). Finally, chronic breast cancer survivors were also less likely than breast cancer survivors treated with CI to share the HCP summary with their health care team (61% vs 73%; P < .01).
DISCUSSION
Using data obtained from an Internet-based SCP tool, we report on patterns in treatment-related effects, follow-up care, and SCP use in patients living with CC. The nature of this platform additionally afforded us the ability to draw robust comparisons with patients treated with CI. In a population of cancer patients whose survivorship needs have been commonly overlooked in both clinical practice and research, we found that CC survivors actively seek survivorship information and support and have greater odds of reporting myriad late and long-term effects of cancer treatment. We additionally show that there is reduced participation of PCPs in the cancer care team and that a lower proportion of SCPs are generated by HCPs for these survivors. Finally, although a substantial number of CC survivors report favorable experiences and levels of satisfaction with this SCP tool, our results suggest that the current version of this tool still leaves CC survivors with unmet needs in comparison with their counterparts treated with CI. These observed disparities were preserved when we compared CC and CI breast cancer survivors because we wanted to explore a CC population that had relatively favorable prognoses. Notably, this report is the one of the first to explore how survivorship care is delivered to and experienced by CC survivors. We demonstrate that CC survivors have higher odds for a multitude of treatment-related effects after adjustments for patient and cancer care characteristics. Some of these symptoms, such as fatigue, have been previously studied and are known to disproportionately affect CC survivors because of the direct effects of treatment, known tumor burden, or psychological distress. 16 Other symptoms, such as peripheral neuropathy and cognitive changes, may be due to the fact that CC patients may be actively receiving maintenance therapy for cancer control. On the other hand, CC survivors and caregivers may not realize or be aware that many of these symptoms are preventable. Although many survivorship care recommendations have been designed for patients after definitive therapy, there are now a handful of resources that address the needs of CC patients from the National Cancer Institute and the American Cancer Society. [17] [18] [19] Furthermore, the National Comprehensive Cancer Network's guidelines for survivorship emphasize that the recommendations are applicable to survivors for whom cancer has become a chronic disease, if clinically appropriate. 20 It is important that continued efforts advance the creation of symptom management guidelines for CC patients. Furthermore, this opportunity highlights the utility of SCPs, wherein the integration of these recommendations could better prepare CC survivors and caregivers to cope with treatment-related effects.
Nearly half of CC patients were managed by their oncologist alone, and they were less likely to be comanaged with a PCP than survivors treated with CI. This is important when we consider that reduced involvement by PCPs after cancer treatment is associated with inferior overall care and outcomes, especially in the delivery of Original Article preventative services and the management of comorbid conditions. 21, 22 Survivors have also expressed that PCPs provide a valuable role in providing emotional support, decision support, supportive care, and patient advocacy. 12 PCPs, however, express uncertainty about their role in survivorship care, and correspondence with oncologic specialists is often poor. 23 SCPs can be used to promote communication between providers of cancer care, especially with respect to identifying which physician should take responsibility for aspects of cancer-related and comorbid disease care as well as psychosocial and decision-making support. When this is coupled with our evidence showing that these survivors may also face a higher burden of longterm treatment-related conditions, it becomes imperative that PCPs be integrated into the cancer care team when they are caring for survivors with CC.
On a similar note, our findings suggest a need for the integration of palliative care specialists into the followup care of this underserved patient population. Not to be viewed as a practice exclusive of survivorship care, the palliative care team can be a natural partner by helping to clarify goals and preferences for care while also providing aggressive symptom management. That the American Society of Clinical Oncology envisions the integration of palliative care into the comprehensive oncology care model by 2020 additionally highlights the embrace of palliative care as a complementary and essential component of oncologic care. 24, 25 The early incorporation of palliative care in the advanced cancer population has been shown to improve both patient and caregiver outcomes, with preliminary evidence also hinting at benefits to patients with early-stage disease. [25] [26] [27] [28] Further research is needed to assess outcomes (eg, quality of life, symptom relief, psychological distress, survival, and satisfaction) when palliative care specialists are involved in the care of CC survivors for whom death is not imminent but is potentially life-limiting.
We found that 15% of all SCPs were generated for CC patients. Because there are no precise estimates available to characterize what percentage of all cancer survivors are living with chronic disease, we cannot definitively conclude whether CC patients are or are not proportionally represented in our sample. We did, however, observe that a lower proportion of SCPs were completed by HCPs for CC patients versus CI patients. Although the Commission on Cancer has issued a standard requiring that cancer survivors be provided with an SCP after active therapy, patients with metastatic disease are excluded from this provision. 9 HCPs may interpret this language to suggest that CC survivors would not benefit from SCPs and, therefore, may not seek survivorship resources for this population. It may also be the case that HCPs are more frequently referring CC patients to palliative care specialists and view these referrals as a preclusion to SCP creation; unfortunately, our tool is unable to capture whether a palliative care team has been involved in the survivor's care. Regardless, a substantial number of SCPs were generated by the survivors themselves or family members, and this suggests that these survivors and their support systems have a vested interest in pursuing survivorship information. Although CC users were relatively satisfied with their SCPs, the proportion was smaller in comparison with CI users. They were also more likely to report that the plan could use more information or did not contain enough information. The relative dissatisfaction expressed by CC respondents may have been prompted more so by the content, rather than the volume, of the information included in the document because advanced and metastatic cancer patients have been shown to endorse a more focused SCP that centers on current management rather than future care or scenarios. 12 That CC survivors are less likely to share the HCP summary with their health care team likely reflects their relative dissatisfaction and may further increase disparities in survivorship support. Given this, our analysis suggests that further customization of this tool is needed because clinical priorities shift once a cure becomes a secondary, if not elusive, endpoint. Querying of additional symptoms that, though not directly related to treatment, significantly affect a cancer survivor's quality of life should be included (eg, depression, anxiety, grief, fear of recurrence, sleep, social functioning, spiritual distress, and financial worries). 10, 11 The provided guidelines should be designed with a CC patient in mind. Finally, SCPs may also provide an opportunity to initiate discussions about goals of care and medical decision making and to introduce the role of a palliative care specialist.
It is important to recognize that the definition of CC covers a broad and heterogeneous population of cancer patients and likely represents a continuum of needs in both survivorship services and palliative care. For example, chronic myelogenous leukemia and chronic lymphocytic leukemia are diseases that follow cycles of recurrence, treatment, and remission that are anticipated, and a single drug can often remain effective even when it is delivered over many years. Conversely, recurrent and metastatic malignancies often take unpredictable directions, and there may be multiple alterations in treatment plans as the face of the disease changes. In an effort to reduce heterogeneity and better approximate how longterm survivors are using SCPs, we elected to conduct a subset analysis of breast cancer survivors because this population may be more amenable to survivorship planning on account of favorable prognoses. Although we did not have data for overall survival, we did observe that chronic breast cancer survivors had a longer time from the initial diagnosis than their chronic nonbreast cancer counterparts, and this supports our hypothesis that this specific subset of survivors has prolonged survival. Overwhelmingly, we observed the same relative disparities in followup care, treatment sequelae, and SCP satisfaction. Although this suggests that cancer chronicity is independent of the prognosis in many aspects of the survivor experience, it is difficult to generalize these results to other cancer sites that carry favorable prognoses in the setting of recurrent/metastatic disease (ie, prostate cancer, colon cancer, and low-grade glioma). Although our analysis serves an important function in highlighting the range of needs that are found across this complex and diverse population, it is imperative to recognize that it, too, is limited by such heterogeneity. Moving forward, we support focused investigations into the needs of distinct patient groups to inform the delivery of more personalized, patient-centered survivorship care and integration of palliative services. Qualitative studies may be particularly valuable to this end by providing detailed descriptions of the emotional and experiential phenomena of CC survivors.
We acknowledge that this analysis included an additional number of limitations. Because data were collected through the method of convenience sampling, we are unable to comment on how our sampled population is different from those who do not engage with the SCP platform. A selection bias may be reflected in our data because patients or proxies facing a particular set of circumstances may be prompted to pursue the creation of an SCP. Self-reporting, however, may mitigate the reporting bias because patients or proxies are less likely to selectively withhold information if no second party, such as an HCP, is present during reporting. It is important to note that breast cancer survivors are overrepresented in our sample, potentially because of widespread advocacy efforts that have increased survivorship awareness for this patient population. Breast cancer survivors are also demographically similar to the groups that frequently engage with the Internet to seek information regarding their healthyoung and female-and this provides an additional explanation of why breast cancer is overrepresented in our sample. 29 In light of the potential biases at play, multivariate modeling was used to best isolate the effect of our variable of interest and eliminate confounders introduced by our sampling method. Overall, we believe that the use of a convenience sample was a reasonable approach in this early investigation because it queried a population about Original Article which little is known. Regardless, the generalization of our results must be applied with healthy skepticism.
Finally, because of the anonymous nature of this reporting system, user profiles were not linked with medical records and limited our ability to corroborate details of cancer diagnoses and treatments. Because the adaptive querying of symptoms was based on these inputs, errors in the reporting of these primary details could lead to failures in querying the appropriate population about relevant symptomatology. We are currently exploring means of extracting data from electronic medical records to autopopulate the care plan platform in hopes of mitigating this issue. 30 As a final note, the application and utility of SCPs are still unclear. Research is ongoing to assess the impact of SCPs on quality of life, survival, and additional outcomes.
In conclusion, a substantial number of survivors dealing with CC, often considered incurable but treatable, seek survivorship information and support. Data from our SCP tool provide early evidence that this population of survivors faces particular disparities in survivorship care in comparison with their counterparts treated with CI; these disparities include a greater burden of treatment-related side effects, reduced participation of PCPs in the cancer care team, and a lower proportion of HCPs generating SCPs for follow-up care. Early integration of palliative care specialists may help to address the unmet needs of this underserved survivor population. Because the definition of CC encompasses a heterogeneous population, we support the investigation of distinct patient groups (eg, by cancer site and locally recurrent versus metastatic) in future studies. Finally, tools to facilitate participation, communication, and coordination of care are valuable to this group of survivors, and future iterations of SCPs should be designed to address the particular circumstances of living with CC.
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